<?xml version="1.0" encoding="UTF-8"?>
<p id="p0590">Two compounds, that is a) the GRL-0617 with an IC
 <sub>50</sub> of 2.4 μM and b) compound 6 with an IC
 <sub>50</sub> of 5.0 μM showed inhibition for SARS-CoV-2 PLpro 
 <xref rid="b0815" ref-type="bibr">[163]</xref>. GRL-0617 and compound 6 were selected and a plaque reduction assay was performed using Vero E6 cells and the SARS-CoV-2 USAWA1/2020; GRL-0617 and compound 6 exhibited EC
 <sub>50</sub> values of 27.6 and 21.0 μM, respectively 
 <xref rid="b0815" ref-type="bibr">[163]</xref>.
</p>
